Literature DB >> 26284549

Characterization of a New Epitope of IRBP That Induces Moderate to Severe Uveoretinitis in Mice With H-2b Haplotype.

Mary J Mattapallil1, Phyllis B Silver1, Lizette M Cortes1, Anthony J St Leger1, Yingyos Jittayasothorn1, Jennifer L Kielczewski1, James J Moon2, Chi-Chao Chan1, Rachel R Caspi1.   

Abstract

PURPOSE: Experimental autoimmune uveitis (EAU) induced in mice using the retinal antigen interphotoreceptor retinoid binding protein (IRBP) is an animal model for posterior uveitis in humans. However, EAU induced by native IRBP protein or its widely used epitope amino acid residues 1 to 20 of human IRBP (hIRBP1-20) is inconsistent, often showing low scores and incidence. We found an urgent need to identify a better pathogenic epitope for the C57BL/6 strain.
METHODS: Mice were immunized with uveitogenic peptides or with native bovine IRBP. Clinical and histological disease and associated immunological responses were evaluated. Truncated and substituted peptides, as well as bioinformatic analyses, were used to identify critical major histocompatibility complex (MHC)/T cell receptor (TCR) contact residues and the minimal core epitope.
RESULTS: The new uveitogenic epitope of IRBP, amino acid residues 651 to 670 of human IRBP (LAQGAYRTAVDLESLASQLT [hIRBP651-670]) is uveitogenic for mice of the H-2b haplotype and elicits EAU with a higher severity and incidence in C57BL/6 mice than the previously characterized hIRBP1-20 epitope. Using truncated and substituted peptides, as well as bioinformatic analysis, we identified the critical contact residues with MHC/TCR and defined the minimal core epitope. This made it possible to design MHC tetramers and use them to detect epitope-specific T cells in the uveitic eye and in lymphoid organs of hIRBP651-670-immunized mice.
CONCLUSIONS: Data suggest that hIRBP651-670 is an epitope naturally processed from a conserved region of native IRBP, potentially explaining its relatively high uveitogenicity. This epitope should be useful for basic and preclinical studies of uveitis in the C57BL/6 model and gives access to genetically engineered mice available on this background.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26284549      PMCID: PMC4544201          DOI: 10.1167/iovs.15-17280

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  25 in total

1.  Residues 1-20 of IRBP and whole IRBP elicit different uveitogenic and immunological responses in interferon gamma deficient mice.

Authors:  D Avichezer; C C Chan; P B Silver; B Wiggert; R R Caspi
Journal:  Exp Eye Res       Date:  2000-08       Impact factor: 3.467

2.  Alternate interactions define the binding of peptides to the MHC molecule IA(b).

Authors:  Xinqi Liu; Shaodong Dai; Frances Crawford; Rachel Fruge; Philippa Marrack; John Kappler
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-25       Impact factor: 11.205

3.  Identification of a new epitope of human IRBP that induces autoimmune uveoretinitis in mice of the H-2b haplotype.

Authors:  D Avichezer; P B Silver; C C Chan; B Wiggert; R R Caspi
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-01       Impact factor: 4.799

4.  Multiple sequence alignment with hierarchical clustering.

Authors:  F Corpet
Journal:  Nucleic Acids Res       Date:  1988-11-25       Impact factor: 16.971

5.  Causes and frequency of blindness in patients with intraocular inflammatory disease.

Authors:  A Rothova; M S Suttorp-van Schulten; W Frits Treffers; A Kijlstra
Journal:  Br J Ophthalmol       Date:  1996-04       Impact factor: 4.638

6.  Identification of a major pathogenic epitope in the human IRBP molecule recognized by mice of the H-2r haplotype.

Authors:  P B Silver; L V Rizzo; C C Chan; L A Donoso; B Wiggert; R R Caspi
Journal:  Invest Ophthalmol Vis Sci       Date:  1995-04       Impact factor: 4.799

7.  Effects of CD8 depletion on retinal soluble antigen induced experimental autoimmune uveoretinitis.

Authors:  V L Calder; Z S Zhao; Y Wang; K Barton; S L Lightman
Journal:  Immunology       Date:  1993-06       Impact factor: 7.397

8.  Functional properties of interphotoreceptor retinoid-binding protein.

Authors:  D R Pepperberg; T L Okajima; H Ripps; G J Chader; B Wiggert
Journal:  Photochem Photobiol       Date:  1991-12       Impact factor: 3.421

9.  A humanized model of experimental autoimmune uveitis in HLA class II transgenic mice.

Authors:  Giuseppina Pennesi; Mary J Mattapallil; Shu-Hui Sun; Dody Avichezer; Phyllis B Silver; Zaruhi Karabekian; Chella S David; Paul A Hargrave; J Hugh McDowell; W Clay Smith; Barbara Wiggert; Larry A Donoso; Chi-Chao Chan; Rachel R Caspi
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

10.  Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study.

Authors:  David C Gritz; Ira G Wong
Journal:  Ophthalmology       Date:  2004-03       Impact factor: 12.079

View more
  23 in total

1.  Autoimmunity to neuroretina in the concurrent absence of IFN-γ and IL-17A is mediated by a GM-CSF-driven eosinophilic inflammation.

Authors:  So Jin Bing; Phyllis B Silver; Yingyos Jittayasothorn; Mary J Mattapallil; Chi-Chao Chan; Reiko Horai; Rachel R Caspi
Journal:  J Autoimmun       Date:  2020-06-24       Impact factor: 7.094

2.  Complement anaphylatoxin receptors C3aR and C5aR are required in the pathogenesis of experimental autoimmune uveitis.

Authors:  Lingjun Zhang; Brent A Bell; Minzhong Yu; Chi-Chao Chan; Neal S Peachey; John Fung; Xiaoming Zhang; Rachel R Caspi; Feng Lin
Journal:  J Leukoc Biol       Date:  2015-09-22       Impact factor: 4.962

3.  Complement-Mediated Activation of the NLRP3 Inflammasome and Its Inhibition by AAV-Mediated Delivery of CD59 in a Model of Uveitis.

Authors:  Binit Kumar; Siobhan M Cashman; Rajendra Kumar-Singh
Journal:  Mol Ther       Date:  2018-03-19       Impact factor: 11.454

4.  Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis.

Authors:  Sarah John; Oliver H Bell; Leslie Wilson; David A Copland; Kathryn L Pepple
Journal:  J Vis Exp       Date:  2021-12-17       Impact factor: 1.355

5.  LYN- and AIRE-mediated tolerance checkpoint defects synergize to trigger organ-specific autoimmunity.

Authors:  Irina Proekt; Corey N Miller; Marion Jeanne; Kayla J Fasano; James J Moon; Clifford A Lowell; Douglas B Gould; Mark S Anderson; Anthony L DeFranco
Journal:  J Clin Invest       Date:  2016-08-29       Impact factor: 14.808

6.  Targeting CD6 for the treatment of experimental autoimmune uveitis.

Authors:  Lingjun Zhang; Yan Li; Wen Qiu; Brent A Bell; Nina Dvorina; William M Baldwin; Nora Singer; Timothy Kern; Rachel R Caspi; David A Fox; Feng Lin
Journal:  J Autoimmun       Date:  2018-02-19       Impact factor: 7.094

7.  Quantitative Assessment of Anterior Segment Inflammation in a Rat Model of Uveitis Using Spectral-Domain Optical Coherence Tomography.

Authors:  Kathryn L Pepple; Woo June Choi; Leslie Wilson; Russell N Van Gelder; Ruikang K Wang
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-07-01       Impact factor: 4.799

8.  In Vivo Bioluminescence Imaging for Longitudinal Monitoring of Inflammation in Animal Models of Uveitis.

Authors:  Michal B Gutowski; Leslie Wilson; Russell N Van Gelder; Kathryn L Pepple
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-03-01       Impact factor: 4.799

9.  Digoxin Inhibits Induction of Experimental Autoimmune Uveitis in Mice, but Causes Severe Retinal Degeneration.

Authors:  Samuel J H Hinshaw; Osato Ogbeifun; Wambui S Wandu; Cancan Lyu; Guangpu Shi; Yichao Li; Haohua Qian; Igal Gery
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-03       Impact factor: 4.799

10.  The Cytokine IL-17A Limits Th17 Pathogenicity via a Negative Feedback Loop Driven by Autocrine Induction of IL-24.

Authors:  Wai Po Chong; Mary J Mattapallil; Kumarkrishna Raychaudhuri; So Jin Bing; Sihan Wu; Yajie Zhong; WeiWei Wang; Zilin Chen; Phyllis B Silver; Yingyos Jittayasothorn; Chi-Chao Chan; Jun Chen; Reiko Horai; Rachel R Caspi
Journal:  Immunity       Date:  2020-07-15       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.